Slide 1: FY22 Results
FY22 Results 7th December 2022 Giulio Cerroni Grant Nash CEO CFO
Slide 2: Nonregulated Disclaimer
Nonregulated Disclaimer This presentation is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing which accompanies it. The information in this presentation is subject to updating, revision and amendment. The information in this presentation, which incl
Slide 3: Driven By Our Purpose
Driven By Our Purpose 3 PUBLIC © IXICO plc 2022
Slide 4: Our purpose drives our culture, our services and our strategy
Our purpose drives our culture, our services and our strategy Our purpose driven approach To advance medicine and human health by turning medical imaging data from clinical trials into clinically meaningful information Our 4 “A” values What we do 1. Innovate 2. Deploy and deliver 3. Value Insights O
Slide 5: Advanced Analytics - Intelligent insights
Advanced Analytics - Intelligent insights • Neuroscience Specialists: Able to tailor services to each client’s trial protocol requirements • Track record of Innovation: Disease specific, AI driven quantitative imaging biomarker analysis. • Rapid expansion of proprietary AI driven analytical tools ac
Slide 6: Extensive Scientific Network
Extensive Scientific Network Working together to study disease specific imaging biomarker data to improve the development of new treatments in neurological diseases PUBLIC © IXICO plc 2022
Slide 7: Our record of delivery
Our record of delivery • Founded in 2004. Revenue generating for over a decade. • More than doubled revenues from £4.1m in 2017 to £8.6m in 2022. • Approximately doubled the number of projects, clients & CNS indications supported since 2020. • Established a global network of over 1,000 imaging centr
Slide 8: FY22 Financials
FY22 Financials 8 PUBLIC © IXICO plc 2022
Slide 9: Reinvesting profits to deliver on our purpose
Reinvesting profits to deliver on our purpose 9.5 9.2 8.6 67 66 1.7 65 1.5 1.5 7.6 61 59 5.4 0.4 -0.7 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 ▪ Expanded client base offset by ▪ Gross margin reflects increased ▪ 18% EBITDA margin; maintaining client trial cessations
Slide 10: Order book more diversified, but impacted by client trial cessations
Order book more diversified, but impacted by client trial cessations 11 new projects; 6 clients; 21.7 3 new clients 19.3 18.8 8.6 15.9 16.0 18.8 12.6 16.0 6.8 2018 2019 2020 2021 2022 30-Sep-21 Revenues Client trial Trial wins 30-Sep-22 descopes and fx ▪ £16m of future years’ revenues contracted at
Slide 11: Order book diversified across trial phases and clients
Order book diversified across trial phases and clients 1.2 2018 0.2 0.1 1.5 4.1 1.0 0.6 2019 1.0 9.3 2.4 17.4 6.2 9.9 2020 7.6 3.5 7.6 2021 2.9 0.8 4.9 4.4 2.2 2.3 0.8 2022 2018 2019 2020 2021 2022 1 2 3 NH Other ▪ Significant diversification (doubling) of clients since 2020 ▪ Rebalancing of the ord
Slide 12: Balance sheet oriented to support investment
Balance sheet oriented to support investment 2.6 7.9 7.9 2.3 12.5 7.3 11.5 6.7 5.8 9.4 7.3 7.9 1.2 0.6 0.1 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 ▪ Strong cash balance & debt free ▪ Investments in technology, focussed on ▪ Net assets up 70% over 5 years and long t
Slide 13: Driven By Our Purpose: Advancing Precision Neurology
Driven By Our Purpose Advancing Precision Neurology 13 PUBLIC © IXICO plc 2022
Slide 14: 2022-2027: "Precision in Neuroscience" Strategy
2022-2027 : “Precision in Neuroscience” Strategy Build Innovate Penetrate Bridge Enhance …commercial … by extending our …early phase trials …the clinical trial …organic growth reach & iCRO data assets & to grow into later to clinical via partnerships scale leading AI biomarker clinical phases diagno
Slide 15: Resurgence in Alzheimer's Disease (AD) drug development
Resurgence in Alzheimer’s Disease (AD) drug development • Biogen’s Aducanumab broke the 18 year stalemate in AD drug development; Setting precedent by FDA for further trials in AD; but controversial approval. • Highlight of CTAD conference (San Francisco, 29th Nov-2nd Dec) was Eisai’s Lecanemab repo
Slide 16: CTAD 2022 attendance, San Francisco
CTAD 2022 attendance, San Francisco. (29th Nov-2nd Dec) 16 PUBLIC © IXICO plc 2022
Slide 17: Strong position in magnetic resonance imaging
Strong position in magnetic resonance imaging IM AGING BIOSENSOR Structural M RI Structural Structure (T1 /MT2) RI PET / SPECT Diffusion (dMRI) Advanced M RI(ASL) Perfusion Actigraphy BOLD (fMRI) Metabolites (MRS) Susceptibility (SWI) Neuromelanin Radiological Read Voxelwise Analysis 2D/3D CASL pCAS
Slide 18: Momentum in molecular imaging
Momentum in molecular imaging Dopamine Amyloid Tau Glucose Inflammation α-synuclein Eligibility Efficacy Launched >24 months ago Launched <24 months ago Roadmap Momentum in developing and deploying molecular imaging biomarkers, covering core measures across CNS indications 18 PUBLIC © IXICO plc 2022
Slide 19: Investment Case
Investment Case 19 PUBLIC © IXICO plc 2022
Slide 20: Investment case
Investment case Emerging Precision in Attractive Barriers to Leader Neuroscience market entry growth strategy • Large societal healthcare • Combining imaging • Difficult area for • Continue to Innovate burden clinical trial services and competitors to enter new imaging modalities • Penetrate & scale